Evidence map›Paper›PMID 39679879›Full record

ReviewJournal of radiation research2024

Impact of Fusobacterium nucleatum in the treatment of cancer, including radiotherapy and its future potential in esophageal cancer.

Manato Ohsawa, Hiromi Nishi, Manabu Emi, Toru Yoshikawa, Yoichi Hamai, Yuta Ibuki, Tomoaki Kurokawa, Ryosuke Hirohata, Nao Kitasaki, Miki Kawada-Matsuo and 3 more

Abstract readReview
In one paragraph

Review in Journal of radiation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. International journal of molecular sciences · 2025
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Manato OhsawaDepartment of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan.
Hiromi NishiDepartment of General Dentistry, Hiroshima University Hospital, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan.
Manabu EmiDepartment of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan.
Toru YoshikawaDepartment of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan.
Yoichi HamaiDepartment of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan.
Yuta IbukiDepartment of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan.
Tomoaki KurokawaDepartment of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan.
Ryosuke HirohataDepartment of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan.
Nao KitasakiDepartment of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan.
Miki Kawada-MatsuoDepartment of Bacteriology, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan.
Hitoshi KomatsuzawaDepartment of Bacteriology, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan.
Hiroyuki KawaguchiDepartment of General Dentistry, Hiroshima University Hospital, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan.
Morihito OkadaDepartment of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advances in multimodality therapy, including surgery, chemotherapy, radiation therapy and chemoradiation, the fatality rate for esophageal cancer remains high. Specifically, Fusobacterium nucleatum, due to its aggregation capacity, has shown a tendency to form biofilms. The biofilm-forming capabilities of microbial communities are of utmost importance in the context of cancer treatment, as they have been shown to drive significant losses in the efficaciousness of various cancer treatments. Therefore, elucidating the dynamics of F. nucleatum will be important for the development of effective treatments for esophageal cancer. Therefore, this review summarizes the current knowledge of F. nucleatum, its involvement in cancer and its impact on chemotherapy and radiation therapy. In conclusion, further research on the role of F. nucleatum is essential for the continued advancement of the treatment of esophageal cancer and patient care.

Indexed as

Esophageal NeoplasmsFusobacterium nucleatumBiofilmsHumanschemotherapyesophageal cancerF. nucleatummicrobiomeradiotherapy

Identifiers

PMID39679879
PMCPMC11647932

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.